Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo covers the month of December 2002, with the report dated December 12, 2002. The filing serves to announce a significant executive appointment within the company's leadership structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance announcement and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Gérard Le Fur as Senior Executive Vice President of Sanofi-Synthélabo, effective December 11, 2002. He retains his existing responsibilities as Executive Vice President in charge of Scientific Affairs.
Management Commentary and Risks
The filing highlights Mr. Le Fur's extensive background, noting he is a doctor in pharmacy and science, a specialist in central nervous system disorders, and the author of over 200 scientific papers. He joined Sanofi in 1986 and has held progressively senior roles in Research and Development. The filing does not discuss specific risks, contingencies, or unusual items.
Key Facts for Investors
- Gérard Le Fur was appointed Senior Executive Vice President on December 11, 2002.
- Mr. Le Fur continues to oversee Scientific Affairs in his existing capacity.
- The filing contains no financial results or forward-looking guidance.
- Mr. Le Fur is a Corresponding Member of the French Academy of Sciences.